153 related articles for article (PubMed ID: 37287907)
1. Mediating immunosuppressive functions: a new perspective on the complex immunological properties of SEMA4D in the tumor microenvironment.
Zeng S; Zhang Z; Ye C; Wang J; Jing C; Li L
Front Oncol; 2023; 13():1171926. PubMed ID: 37287907
[TBL] [Abstract][Full Text] [Related]
2. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
3. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
Younis RH; Han KL; Webb TJ
J Immunol; 2016 Feb; 196(3):1419-29. PubMed ID: 26740106
[TBL] [Abstract][Full Text] [Related]
4. The Potential Immunomodulatory Roles of Semaphorin 4D in Human Periapical Lesions.
Zeng Y; Wang L; Liu L; Wang M; Yan L; Ye L; Song D; Huang D
J Endod; 2023 Jan; 49(1):62-68. PubMed ID: 36257402
[TBL] [Abstract][Full Text] [Related]
5. Sema4D is required in both the adaptive and innate immune responses of contact hypersensitivity.
Zhu Z; Luo Y; Yu J; Gao J; Zhang Y; Xiao C; Zhang C; Wang G; Liu Y; Fu M; Yao X; Li W
Mol Immunol; 2016 Oct; 78():98-104. PubMed ID: 27614265
[TBL] [Abstract][Full Text] [Related]
6. The Pan-Cancer Crosstalk Between the
Xie R; Yuan M; Jiang Y
Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
[No Abstract] [Full Text] [Related]
7.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
8. Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.
Wang D; Peng L; Hua L; Li J; Liu Y; Zhou Y
Front Cell Dev Biol; 2022; 10():817800. PubMed ID: 35141222
[No Abstract] [Full Text] [Related]
9. The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer.
Jiang H; Chen C; Sun Q; Wu J; Qiu L; Gao C; Liu W; Yang J; Jun N; Dong J
Onco Targets Ther; 2016; 9():5737-5750. PubMed ID: 27729799
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
11. The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Lontos K; Adamik J; Tsagianni A; Galson DL; Chirgwin JM; Suvannasankha A
Front Endocrinol (Lausanne); 2018; 9():322. PubMed ID: 29971044
[TBL] [Abstract][Full Text] [Related]
12. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Molecular Characterization of m
Zhu J; Xiao J; Wang M; Hu D
Front Oncol; 2020; 10():618374. PubMed ID: 33585244
[TBL] [Abstract][Full Text] [Related]
14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of
Wang X; Tang Y; Liu R; Li W; Liu S; Zhou X
Biotechnol Genet Eng Rev; 2023 Mar; ():1-23. PubMed ID: 36989393
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
Ji H; Ren M; Liu T; Sun Y
Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
[TBL] [Abstract][Full Text] [Related]
18. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
19. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
20. Immunological role and prognostic potential of CLEC10A in pan-cancer.
Qin Y; Wang L; Zhang L; Li J; Liao L; Huang L; Li W; Yang J
Am J Transl Res; 2022; 14(5):2844-2860. PubMed ID: 35702069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
